| dc.contributor.author | Berry, JM | en_US |
| dc.contributor.author | Howard, PW | en_US |
| dc.contributor.author | Kelland, LR | en_US |
| dc.contributor.author | Thurston, DE | en_US |
| dc.date.accessioned | 2018-09-18T10:35:40Z | |
| dc.date.issued | 2002-05-20 | en_US |
| dc.identifier | 10 | en_US |
| dc.identifier.citation | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 pp. 1413 - 1416 | en_US |
| dc.identifier.issn | 0960-894X | en_US |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/2761 | |
| dc.identifier.doi | 10.1016/S0960-894X(02)00150-6 | en_US |
| dc.description.abstract | The first example of an N10-protected. (e.g., Psec, 15) pyrrolo[2,1-c][1,4]benzodiazepine (PBD) analogue that retains significant cytotoxicity in a number of tumour cell lines is reported. This prototype could lead to a new generation of clinically useful N10-protceted PBD prodrugs. (C) 2002 Published by Elsevier Science Ltd. | en_US |
| dc.format.extent | 1413 - 1416 | en_US |
| dc.title | Synthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug | en_US |
| dc.type | Journal Article | |
| rioxxterms.versionofrecord | 10.1016/S0960-894X(02)00150-6 | en_US |
| rioxxterms.licenseref.startdate | 2002-05-20 | en_US |
| rioxxterms.type | Journal Article/Review | en_US |
| dc.relation.isPartOf | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | en_US |
| pubs.notes | article-number: PII S0960-894X(02)00150-6 unique-id: ISI:000175648800020 | en_US |
| pubs.notes | Not known | en_US |
| pubs.organisational-group | /ICR | |
| pubs.volume | 12 | en_US |
| pubs.embargo.terms | Not known | en_US |
| dc.contributor.icrauthor | Kelland, Lloyd | en_US |
